ABT Insider Trading | Abbott Laboratories Buys and Sells

ABT Insider Trading

Insider Ownership Percentage: 0.46%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $35,443,137.40

Abbott Laboratories Insider Trading History Chart

This chart shows the insider buying and selling history at Abbott Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$15MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Abbott Laboratories Share Price & Price History

Current Price: $130.81
Price Change: Price Decrease of -0.54 (-0.41%)
As of 03/28/2025 04:59 PM ET

This chart shows the closing price history over time for ABT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$130.81Closing price on 03/28/25:

SEC Filings (Institutional Ownership Changes) for Abbott Laboratories (NYSE:ABT)

75.18% of Abbott Laboratories stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ABT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$9.77Bbought$3.76BsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200B-$100B$0$100B$200BTotal InflowsTotal Outflows
Abbott Laboratories logo
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Read More on Abbott Laboratories

Today's Range

Now: $130.81
Low: $130.75
High: $133.46

50 Day Range

MA: $130.05
Low: $113.45
High: $140.13

52 Week Range

Now: $130.81
Low: $99.71
High: $141.23

Volume

6,708,271 shs

Average Volume

5,857,870 shs

Market Capitalization

$226.87 billion

P/E Ratio

17.10

Dividend Yield

1.86%

Beta

0.7

Who are the company insiders with the largest holdings of Abbott Laboratories?

Abbott Laboratories' top insider investors include:
  1. Daniel J Starks (Director)
  2. Robert B Ford (CEO)
  3. Jr Robert E Funck (EVP)
  4. Daniel Gesua Sive Salvadori (EVP)
  5. Andrea F Wainer (EVP)
  6. Lisa D Earnhardt (EVP)
  7. Eric Shroff (SVP)
  8. John A Jr Mccoy (VP)
Learn More about top insider investors at Abbott Laboratories.

Who are the major institutional investors of Abbott Laboratories?

Abbott Laboratories' top institutional shareholders include:
  1. Vanguard Group Inc. — 9.72%
  2. Capital International Investors — 3.92%
  3. Capital Research Global Investors — 3.12%
  4. Geode Capital Management LLC — 2.06%
  5. Wellington Management Group LLP — 1.52%
  6. Northern Trust Corp — 1.27%
Learn More about top institutional investors of Abbott Laboratories stock.

Which institutional investors are selling Abbott Laboratories stock?

In the previous quarter, ABT stock was sold by these institutional investors:
  1. Legal & General Group Plc
  2. Two Sigma Advisers LP
  3. Arrowstreet Capital Limited Partnership
  4. International Assets Investment Management LLC
  5. Two Sigma Investments LP
  6. Polen Capital Management LLC
  7. Menora Mivtachim Holdings LTD.
  8. Voya Investment Management LLC
Within the previous year, company insiders that have sold Abbott Laboratories company stock include:
  1. Daniel J Starks (Director)
  2. Robert B Ford (CEO)
  3. Jr Robert E Funck (EVP)
  4. Daniel Gesua Sive Salvadori (EVP)
  5. Andrea F Wainer (EVP)
  6. Lisa D Earnhardt (EVP)
  7. Eric Shroff (SVP)
Learn More investors selling Abbott Laboratories stock.

Which institutional investors are buying Abbott Laboratories stock?

During the previous quarter, ABT stock was acquired by institutional investors including:
  1. Norges Bank
  2. T. Rowe Price Investment Management Inc.
  3. Raymond James Financial Inc.
  4. Capital International Investors
  5. Northern Trust Corp
  6. Invesco Ltd.
  7. APG Asset Management N.V.
  8. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC